Biological activity
| In pharmacology, biological activity or pharmacological activity describes the beneficial or adverse effects of a drug on living matter.[1][2] When a drug is a complex chemical mixture, this activity is exerted by the substance's active ingredient or pharmacophore but can be modified by the other constituents. Among the various properties of chemical compounds, pharmacological/biological activity plays a crucial role since it suggests uses of the compounds in the medical applications. However, chemical compounds may show some adverse and toxic effects which may prevent their use in medical practice. |
Activity is generally dosage-dependent. Further, it is common to have effects ranging from beneficial to adverse for one substance when going from low to high doses. Activity depends critically on fulfillment of the ADME criteria. To be an effective drug, a compound not only must be active against a target, but also possess the appropriate ADME (Absorption, Distribution, Metabolism, and Excretion) properties necessary to make it suitable for use as a drug.[3]
Whereas a material is considered bioactive if it has interaction with or effect on any cell tissue in the human body, pharmacological activity is usually taken to describe beneficial effects, i.e. the effects of drug candidates as well as a substance's toxicity.
In the study of biomineralisation, bioactivity is often meant as the formation of calcium phosphate deposits on the surface of objects placed in simulated body fluid, a buffer solution with ion content similar to blood.
See also[edit]
- Lipinski's Rule of Five, describing molecular properties of drugs
- QSAR, quantitative structure-activity relationship
- Chemical property
- Molecular property
- Physical property
- Chemical structure
References[edit]
- Jump up ^ Etymology: Gk, bios, life; L, activus, with energy, Mosby's Medical Dictionary, 8th edition. © 2009, Elsevier.
- Jump up ^ Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc.
- Jump up ^ A.Jagan Mohan Reddy; Manas Ranjan Barik; Gajendra L. Muli & Parthasarathy.T (2012). "Computational Approach for Designing and Development of Potent Inhibitor for Hepatitis - B Virus X- Associated Protein through Molecular Docking Studies". Journal of Chemical and Pharmaceutical Research. 4 (1): 265–271.
